Rafael Holdings, Inc., often simply known as RFL, is a diversified holding company well-known for its investments in commercial real estate and interest in pharmaceutical and medical technology companies. The company is designed to serve as a platform that furthers the development of life-altering treatments for seriously unmet medical needs. It is renowned for its style of actively managing its investments along with seeking additional opportunities in the real estate and biomedical sectors.
Founded in 2018 and headquartered in Newark, New Jersey, Rafael Holdings, Inc. is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol RFL. Succeeding IDT Corporation's disposition of its holdings in CTI BioPharma Corp, as well as Rafael Pharmaceuticals, Inc. along with certain real estate assets, RFL became an independent public company.
Rafael Holdings, Inc. owns significant commercial real estate assets in Baltimore, Maryland, Piscataway and Newark, New Jersey. The real estate holdings are crucially instrumental to the company in yielding significant returns. They also provide a strategic advantage for its life science companies as they aim to establish themselves as industry leaders.
RFL's medical-tech investment portfolio primarily includes Rafael Pharmaceuticals, Inc., a notable clinical-stage metabolic oncology therapeutics company. Rafael Pharmaceuticals specializes in the development of highly selective and broadly acting anti-cancer agents, showing promise in treating a range of tumors, such as acute myeloid leukemia (AML) Pancreatic Cancer, and others. The efforts of Rafael Pharmaceuticals align with RFL's mission of meeting serious unmet medical needs.
This forward-thinking holding company has demonstrated a keen eye for prospective opportunities within its chosen sectors. Rafael Holdings, Inc. continues to add to its portfolio and seeks to maximize the value of its assets. It leverages its financial strength to support the growth of its holdings, focusing on fostering innovations in biomedicine and pharmaceuticals that genuinely contribute to bettering health outcomes for patients.
RFL fosters a unique business ecosystem, facilitating a flexible and innovation-friendly environment for its holdings. Through its active management style and targeted investments, Rafael Holdings, Inc. capitalizes on its position as an investor to influence the direction of operations in its biomedical and real estate ventures. Its strategic approach has been contributing effectively to the value it is adding to its shareholders, employees, and most importantly, to the patients who ultimately benefit from the medicinal breakthroughs it helps to facilitate.